STE Gears Up for Q3 Earnings: Here's What You Need to Know
STERIS' third-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog and increasing bioprocessing demand.
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Steris (STE) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Strategic Acquisitions to Support STERIS Stock Amid Macro Issues
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
STERIS Gains From Expanded Product Offerings Amid Macro Issues
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
Reasons to Retain STE Stock in Your Portfolio Now
STERIS' strong prospects in the healthcare business bode well for investors.
Why Is Steris (STE) Up 0.9% Since Last Earnings Report?
Steris (STE) reported earnings 30 days ago. What's next for the stock?
New Alliances to Support STERIS Stock Despite Macro Issues
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business.
Why Steris (STE) International Revenue Trends Deserve Your Attention
Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
STE Q2 Earnings Beat Estimates, Margins Dip, Stock Gains in Aftermarket
STERIS' second-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of both margins is concerning.
Compared to Estimates, Steris (STE) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
